检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]湖南中医药大学,湖南长沙410208 [2]湖南中医药大学第一附属医院,湖南长沙410073
出 处:《安徽中医药大学学报》2017年第6期17-20,共4页Journal of Anhui University of Chinese Medicine
基 金:湖南省教育厅一般项目(17c1235)
摘 要:目的观察犀黄丸对火毒血瘀型鼻咽癌放射治疗患者生活质量的影响。方法将60例鼻咽癌患者随机分为实验组和对照组,每组30例。对照组仅接受放射治疗,实验组加用犀黄丸口服。观察并比较两组患者治疗前后中医证候积分,比较两组患者生活质量改善情况及不良反应。结果两组患者治疗后中医证候积分均显著降低(P<0.05),实验组中医证候积分下降程度大于对照组(P<0.05);实验组患者生活质量的改善优于对照组(P<0.05);实验组总不良反应率(50.00%)与对照组(73.33%)比较,差异无统计学意义(P>0.05)。结论犀黄丸可改善鼻咽癌患者的临床症状,提高患者生活质量,减少放射治疗的不良反应。Objective To investigate the effect of Xihuang Pill on the quality of life of patients with naso- pharyngeal carcinoma with fire toxin and blood stasis treated with radiotherapy. Methods A total of 60 patients with nasopharyngealcarcinoma were randomly divided into experimental group and control group, with 30 patients in each group. The patients in the control group were given radiotherapy alone, while those in the experimental group were given oral Xihuang Pill in addition to radiotherapy. The two groups were compared in terms of traditional Chinese medicine (TCM) syndrome score before and after treatment, improvement in quality of life, and adverse reactions. Results Both groups had a significant reduction in TCM syndrome score after treatment (P〈0.05), and the experiment group had a significantly greater reduction than the control group (P〈0.05). The experiment group had a significantly better improvement in quality of life than the control group (P〈0.05). There was no significant difference in the incidence rate of adverse reactions be- tween the experimental group and the control group (50.00% vs 73.33%, P〉0.05). Conclusion Xihuang Pill can relieve the clinical symptoms of patients with nasopharyngeal carcinoma, improve their quality of life, and reduce the incidence rate of adverse reactions of radiotherapy.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.38